Thomas Vanzandt, O.D.
NPI 1336178672 · Optometrist · Brandon, FL
Enrolled with Medicare as Practitioner - Optometry · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1336178672
- Entity type
- Individual
- Primary specialty
- OptometristEye and Vision Services Providers
- Credential
- O.D.
- Sex
- Male
- Sole proprietor
- No
- License
- OPC2135 (FL)
Specialties & taxonomies
Eye and Vision Services Providers
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
19 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
410 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Exam of Visual Field With Extended Testing92083 | 70 | $62 |
| Photography of the Retina92250 | 58 | $34 |
| Established Patient Problem Focused Exam of Visual System92012 | 48 | $87 |
| New Patient Complete Exam of Visual System92004 | 46 | $148 |
| Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More99214 | 40 | $129 |
| Established Patient Complete Exam of Visual System92014 | 36 | $125 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 8 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Latanoprost | 86 | 43 |
| Cyclosporinebrand: Restasis | 33 | 21 |
| Prednisolone Acetate | 22 | 18 |
| Lifitegrastbrand: Xiidra | 18 | — |
| Dorzolamide Hcl/Timolol Maleatbrand: Dorzolamide-Timolol | 17 | — |
| Timolol Maleate | 17 | 11 |
| Brimonidine Tartrate/Timololbrand: Brimonidine Tartrate-Timolol | 15 | — |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$718 across 27 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2006-06-30
- Last updated
- 2023-10-04
- Certified
- 2023-10-04
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.